Abstract:Importance Pulmonary arterial hypertension (PAH) is a subtype of pulmonary hypertension (PH), characterized by pulmonary arterial remodeling. The prevalence of PAH is approximately 10.6 cases per 1 million adults in the US. Untreated, PAH progresses to right heart failure and death. Observations Pulmonary hypertension is defined by a mean pulmonary artery pressure greater than 20 mm Hg and is classified into 5 clinical groups based on etiology, pathophysiology, and treatment. Pulmonary arterial hypertension is 1 of the 5 groups of PH and is hemodynamically defined by right heart catheterization demonstrating a mean pulmonary artery pressure greater than 20 mm Hg, a pulmonary artery wedge pressure of 15 mm Hg or lower, and a pulmonary vascular resistance of 3 Wood units or greater. Pulmonary arterial hypertension is further divided into subgroups based on underlying etiology, consisting of idiopathic PAH, heritable PAH, drug- and toxin-associated PAH, pulmonary veno-occlusive disease, PAH in long-term responders to calcium channel blockers, and persistent PH of the newborn, as well as PAH associated with other medical conditions including connective tissue disease, HIV, and congenital heart disease. Early presenting symptoms are nonspecific and typically consist of dyspnea on exertion and fatigue. Currently approved therapy for PAH consists of drugs that enhance the nitric oxide-cyclic guanosine monophosphate biological pathway (sildenafil, tadalafil, or riociguat), prostacyclin pathway agonists (epoprostenol or treprostinil), and endothelin pathway antagonists (bosentan and ambrisentan). With these PAH-specific therapies, 5-year survival has improved from 34% in 1991 to more than 60% in 2015. Current treatment consists of combination drug therapy that targets more than 1 biological pathway, such as the nitric oxide-cyclic guanosine monophosphate and endothelin pathways (eg, ambrisentan and tadalafil), and has shown demonstrable improvement in morbidity and mortality compared with the previous conventional single-pathway targeted monotherapy. Conclusions and Relevance Pulmonary arterial hypertension affects an estimated 10.6 per 1 million adults in the US and, without treatment, typically progresses to right heart failure and death. First-line therapy with drug combinations that target multiple biological pathways are associated with improved survival.

Medical Management of Right Ventricular Dysfunction in Pulmonary Arterial Hypertension

Medical Management of Pulmonary Arterial Hypertension: Current Approaches and Investigational Drugs

Aggressive Afterload Lowering to Improve the Right Ventricle: A New Target for Medical Therapy in Pulmonary Arterial Hypertension?

Management of Right Ventricular Failure in Pulmonary Hypertension (and After LVAD Implantation)

Diagnosis and Treatment of Pulmonary Arterial Hypertension: A Review.

Risk stratification and medical therapy of pulmonary arterial hypertension

Recent Advances in the Treatment of Pulmonary Arterial Hypertension

Mechanisms and treatment of pulmonary arterial hypertension

Progress in Pharmacological Treatment of Pulmonary Arterial Hypertension

Right ventricular failure in pulmonary hypertension: recent insights from experimental models

Treatments for Pulmonary Arterial Hypertension

Autonomic nervous system involvement in pulmonary arterial hypertension

Pharmacotherapy of refractory pulmonary arterial hypertension

The Future of PAH Treatment

New and Emerging Therapeutic Drugs for the Treatment of Pulmonary Arterial Hypertension: A Systematic Review

Pathophysiology of the right ventricle and its pulmonary vascular interaction

Contemporary Treatment of Pulmonary Arterial Hypertension: A U.S. Perspective

Current Approaches to the Treatment of Systemic-Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)

An Emerging Strategy for Targeted Therapy of Pulmonary Arterial Hypertension: Vasodilation Plus Vascular Remodeling Inhibition

Right ventricular assessment in pulmonary hypertension

The right ventricle and pulmonary hypertension